Novel Dent disease 1 cellular models reveal biological processes underlying ClC-5 loss-of-function.


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
09 07 2021
Historique:
received: 08 02 2021
revised: 23 04 2021
accepted: 26 04 2021
pubmed: 15 5 2021
medline: 26 3 2022
entrez: 14 5 2021
Statut: ppublish

Résumé

Dent disease 1 (DD1) is a rare X-linked renal proximal tubulopathy characterized by low molecular weight proteinuria and variable degree of hypercalciuria, nephrocalcinosis and/or nephrolithiasis, progressing to chronic kidney disease. Although mutations in the electrogenic Cl-/H+ antiporter ClC-5, which impair endocytic uptake in proximal tubule cells, cause the disease, there is poor genotype-phenotype correlation and their contribution to proximal tubule dysfunction remains unclear. To further discover the mechanisms linking ClC-5 loss-of-function to proximal tubule dysfunction, we have generated novel DD1 cellular models depleted of ClC-5 and carrying ClC-5 mutants p.(Val523del), p.(Glu527Asp) and p.(Ile524Lys) using the human proximal tubule-derived RPTEC/TERT1 cell line. Our DD1 cellular models exhibit impaired albumin endocytosis, increased substrate adhesion and decreased collective migration, correlating with a less differentiated epithelial phenotype. Despite sharing functional features, these DD1 cell models exhibit different gene expression profiles, being p.(Val523del) ClC-5 the mutation showing the largest differences. Gene set enrichment analysis pointed to kidney development, anion homeostasis, organic acid transport, extracellular matrix organization and cell-migration biological processes as the most likely involved in DD1 pathophysiology. In conclusion, our results revealed the pathways linking ClC-5 mutations with tubular dysfunction and, importantly, provide new cellular models to further study DD1 pathophysiology.

Identifiants

pubmed: 33987651
pii: 6275366
doi: 10.1093/hmg/ddab131
pmc: PMC8283206
doi:

Substances chimiques

CLC-5 chloride channel 0
Chloride Channels 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1413-1428

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press.

Références

Gene. 2020 Jul 15;747:144662
pubmed: 32289351
Pflugers Arch. 2008 Jan;455(4):583-93
pubmed: 17661077
Clin J Am Soc Nephrol. 2012 Jul;7(7):1179-87
pubmed: 22516291
Nat Protoc. 2019 Feb;14(2):482-517
pubmed: 30664679
Am J Kidney Dis. 2001 Jan;37(1):138-143
pubmed: 11136179
Nephron Physiol. 2009;112(4):p53-62
pubmed: 19546591
Kidney Int. 1998 Jan;53(1):3-17
pubmed: 9452994
J Microsc. 2006 Dec;224(Pt 3):213-32
pubmed: 17210054
Compr Physiol. 2013 Jul;3(3):1079-123
pubmed: 23897681
Kidney Int. 2000 Jan;57(1):240-9
pubmed: 10620205
Pharmacol Rev. 2020 Jan;72(1):343-379
pubmed: 31882442
J Physiol. 2015 Sep 15;593(18):4151-64
pubmed: 25820368
Pflugers Arch. 2012 Feb;463(2):247-56
pubmed: 22083641
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8075-80
pubmed: 9653142
Kidney Int. 2008 Jul;74(1):52-61
pubmed: 18322545
Oncogene. 2014 Jul 31;33(31):4021-35
pubmed: 24037532
Hum Mutat. 2015 Aug;36(8):743-52
pubmed: 25907713
J Mol Cell Biol. 2020 Jul 1;12(7):499-514
pubmed: 32162654
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):7014-9
pubmed: 23572577
J Biol Chem. 2006 Jun 9;281(23):16068-77
pubmed: 16601121
Am J Physiol Renal Physiol. 2009 Feb;296(2):F390-7
pubmed: 19019917
J Immunol. 2010 Apr 1;184(7):3988-96
pubmed: 20181886
Hum Mol Genet. 1999 Feb;8(2):247-57
pubmed: 9931332
J Pediatr Genet. 2013 Sep;2(3):133-40
pubmed: 27625851
Nature. 2000 Nov 16;408(6810):369-73
pubmed: 11099045
J Bone Miner Res. 2003 Apr;18(4):615-23
pubmed: 12674322
J Mol Cell Biol. 2019 Jan 1;11(1):1-13
pubmed: 30239845
Cell Mol Life Sci. 2015 Jun;72(11):2119-34
pubmed: 25681867
Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F767-F780
pubmed: 28539339
Hum Mol Genet. 1997 Aug;6(8):1233-9
pubmed: 9259268
Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):95-105
pubmed: 25500123
J Proteomics. 2016 Jan 1;130:26-32
pubmed: 26370164
Orphanet J Rare Dis. 2010 Oct 14;5:28
pubmed: 20946626
Kidney Int. 2006 Jul;70(1):79-87
pubmed: 16672909
Methods Enzymol. 2011;490:71-92
pubmed: 21266244
Kidney Int. 2009 Nov;76(9):999-1005
pubmed: 19657328
J Biol Chem. 1995 Dec 29;270(52):31172-7
pubmed: 8537381
J Gen Physiol. 1997 Aug;110(2):165-71
pubmed: 9236209
Sci Rep. 2016 Dec 19;6:39470
pubmed: 27991585
Int J Mol Sci. 2020 Jan 14;21(2):
pubmed: 31947599
N Engl J Med. 1999 Apr 15;340(15):1177-87
pubmed: 10202170
Kidney Int. 2016 Aug;90(2):430-439
pubmed: 27342959
Physiol Genomics. 2008 May 13;33(3):341-54
pubmed: 18349385
Function (Oxf). 2020;1(2):zqaa017
pubmed: 33015630
Sci Rep. 2019 Jan 29;9(1):913
pubmed: 30696889
World J Nephrol. 2017 Jan 6;6(1):14-20
pubmed: 28101447
Biochem J. 2013 Jun 15;452(3):391-400
pubmed: 23566014
J Cell Physiol. 2007 Feb;210(2):479-88
pubmed: 17111367
J Nephrol. 2016 Jun;29(3):349-357
pubmed: 26943181
Annu Rev Physiol. 2017 Feb 10;79:425-448
pubmed: 27813828
Kidney Int. 2020 Sep;98(3):549-552
pubmed: 32828237
Hum Mol Genet. 2000 Dec 12;9(20):2937-45
pubmed: 11115837
Am J Physiol Renal Physiol. 2008 Nov;295(5):F1365-75
pubmed: 18715936
Am J Physiol Renal Physiol. 2021 Feb 1;320(2):F145-F160
pubmed: 33283647

Auteurs

Mónica Durán (M)

Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR)-CIBBIM Nanomedicine, Barcelona, Spain.

Carla Burballa (C)

Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR)-CIBBIM Nanomedicine, Barcelona, Spain.
Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.

Gerard Cantero-Recasens (G)

Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR)-CIBBIM Nanomedicine, Barcelona, Spain.

Cristian M Butnaru (CM)

Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.

Vivek Malhotra (V)

Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.

Gema Ariceta (G)

Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR)-CIBBIM Nanomedicine, Barcelona, Spain.
Pediatric Nephrology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

Eduard Sarró (E)

Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR)-CIBBIM Nanomedicine, Barcelona, Spain.

Anna Meseguer (A)

Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR)-CIBBIM Nanomedicine, Barcelona, Spain.
Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Medicina, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III-FEDER, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH